文献速递重症综合管理与镇静镇痛

医学ICU患者住院全程抗阻训练联合或不联合β-羟基-β-甲基丁酸的多水平干预:四臂多中心随机对照试验

Effects of a multilevel intervention of resistance training with or without beta-hydroxy-beta-methylbutyrate in medical ICU patients during entire hospitalisation: a four-arm multicentre randomised controlled trial.
PubMed 文献 · Crit Care · 2023-12-15
一句话结论医学ICU患者住院全程抗阻训练联合或不联合HMB可改善出院时躯体功能和肌力,但未改善肌肉量、生活质量或60天死亡率。

这项四臂多中心单盲随机对照试验纳入112例内科诊断的成人ICU患者,随机分为抗阻训练组、HMB组(3 g/天HMBCa)、联合组和对照组,从ICU至普通病房直至出院进行干预。抗阻训练组和联合组出院时SPPB评分分别较对照组增加3.848分和2.832分,6MWD分别增加99.768 m和88.577 m(均P<0.01);HMB组无显著变化。抗阻训练组和联合组在ICU出院和医院出院时MRC评分及握力有统计学显著改善(P<0.05)。各组间60天死亡率、ICU-AW发生率、肌肉量、生活质量及其他功能方面无显著差异。

要点

  • 医学ICU成人患者住院全程抗阻训练(联合或不联合HMB)可改善出院时SPPB评分(分别增加3.848分和2.832分,均P<0.01)。
  • 抗阻训练组和联合组6MWD分别较对照组增加99.768 m和88.577 m(均P<0.01),HMB组无显著变化。
  • 抗阻训练组和联合组在ICU出院和医院出院时MRC评分及握力有统计学显著改善(P<0.05)。
  • 各组间60天死亡率、ICU-AW发生率、肌肉量、生活质量及其他功能方面无显著差异。
  • 单独HMB 3 g/天HMBCa未能显著改善任何主要或次要结局。

适用人群与场景

  • 纳入112例成人内科诊断入住ICU的患者,随机分入四组,干预从ICU至普通病房直至出院。

处置流程与药物剂量

  • 抗阻训练组接受方案化的多水平抗阻运动;HMB组接受3 g/天HMBCa;联合组接受抗阻训练联合HMB;对照组接受标准治疗;干预从ICU至普通病房直至出院。

研究设计与关键结果

  • 研究类型为多中心、四臂、单盲随机对照试验,共纳入112例成人内科ICU患者,随机分为抗阻训练组、HMB组(3 g/天HMBCa)、联合组和对照组,从ICU至普通病房直至出院进行干预,采用广义线性混合模型按意向性治疗原则分析。
  • 主要结局出院时SPPB评分:抗阻训练组较对照组增加3.848分,联合组较对照组增加2.832分(均P<0.01);HMB组无显著变化。
  • 主要结局出院时6MWD:抗阻训练组较对照组增加99.768 m,联合组较对照组增加88.577 m(均P<0.01);HMB组无显著变化。
  • 次要结局:抗阻训练组和联合组在ICU出院和医院出院时MRC评分及握力有统计学显著改善(P<0.05)。
  • 各组间60天死亡率、ICU-AW发生率、肌肉量、生活质量及其他功能方面无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、四臂、单盲随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,住院全程抗阻训练联合或不联合HMB可改善医学ICU患者的躯体功能和肌力,但肌肉量、生活质量和60天死亡率未受影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intensive care unit-acquired weakness (ICU-AW) is a prevalent and severe issue among ICU patients. Resistance training and beta-hydroxy-beta-methylbutyrate (HMB) intervention have demonstrated the potential to enhance muscle function in patients with sarcopenia and in older adults. The purpose of this study was to determine whether resistance training and/or HMB administration would improve physical function, muscle strength, and quality of life in medical ICU patients.

METHODS: In this multicentre, four-arm, single-blind randomised control trial, a total of 112 adult patients with internal medical diagnoses admitted to the ICU were enrolled. These participants were then randomly assigned to one of four treatment groups: the resistance training group received protocol-based multilevel resistance exercise, the HMB group received 3 g/day of HMBCa, combination group and control groups received standard care, from the ICU to the general ward until discharge. The primary outcomes assessed at discharge included six-minute walking distance (6MWD) and short physical performance battery (SPPB). Secondary outcomes measured included muscle mass, MRC score, grip strength, and health reports quality of life at different time points. Data analysis was performed using a generalised linear mixed model, adhering to the principles of intention-to-treat analysis.

RESULTS: Resistance training and combination treatment groups exhibited significant increases in SPPB scores (3.848 and 2.832 points, respectively) compared to the control group and substantial improvements in 6WMD (99.768 and 88.577 m, respectively) (all with P < 0.01). However, no significant changes were observed in the HMB group. Muscle strength, as indicated by MRC and grip strength tests conducted at both ICU and hospital discharge, showed statistically significant improvements in the resistance training and combination groups (P < 0.05). Nevertheless, no significant differences were found between the treatment groups and usual care in terms of 60-day mortality, prevalence of ICU-AW, muscle mass, quality of life, or other functional aspects.

CONCLUSIONS: Resistance training with or without beta-hydroxy-beta-methylbutyrate during the entire hospitalisation intervention improves physical function and muscle strength in medical ICU patients, but muscle mass, quality of life, and 60-day mortality were unaffected.

TRIAL REGISTRATION: ChiCTR2200057685 was registered on March 15th, 2022.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Wu TT, Chen QL, Lin XX, et al. Effects of a multilevel intervention of resistance training with or without beta-hydroxy-beta-methylbutyrate in medical ICU patients during entire hospitalisation: a four-arm multicentre randomised controlled trial. Crit Care. 2023. PMID: 38102705. doi:10.1186/s13054-023-04698-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。